Cargando…

An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes

PURPOSE: Continuous Glucose Monitoring (CGM) is a key tool for insulin-treated people with diabetes (PwD). CGM devices include both real-time CGM (rtCGM) and intermittently scanned CGM (isCGM), which are associated with an improvement of glucose control and less hypoglycemia in clinical trials of pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maiorino, Maria Ida, Buzzetti, Raffaella, Irace, Concetta, Laviola, Luigi, Napoli, Nicola, Pitocco, Dario, Esposito, Katherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543826/ https://www.ncbi.nlm.nih.gov/pubmed/37676398 http://dx.doi.org/10.1007/s12020-023-03473-w

Ejemplares similares

Teleassistance for Patients With Type 1 Diabetes During the COVID-19 Pandemic: Results of a Pilot Study
por: Parise, Martina, et al.
Publicado: (2021)

Clinical use of a 180‐day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes
por: Irace, Concetta, et al.
Publicado: (2020)

Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials
por: Giugliano, Dario, et al.
Publicado: (2019)

Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study
por: Deiss, Dorothee, et al.
Publicado: (2020)

Efficacy of Insulin Analogs in Achieving the Hemoglobin A(1c) Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials
por: Giugliano, Dario, et al.
Publicado: (2011)

Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
por: Maiorino, Maria Ida, et al.
Publicado: (2021)

The residual cardiorenal risk in type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021)

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
por: Giugliano, Dario, et al.
Publicado: (2021)

A Head-to-Head Comparison of Two Algorithms for Adjusting Mealtime Insulin Doses Based on CGM Trend Arrows in Adult Patients with Type 1 Diabetes: Results from an Exploratory Study
por: Parise, Martina, et al.
Publicado: (2023)

Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
por: Longo, Miriam, et al.
Publicado: (2022)

Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital
por: Umpierrez, Guillermo E., et al.
Publicado: (2018)

Continuous Glucose Monitoring in Women with Normal OGTT in Pregnancy
por: Tartaglione, Linda, et al.
Publicado: (2021)

Sexual dysfunctions and short-term glucose variability in young men with type 1 diabetes
por: Caruso, Paola, et al.
Publicado: (2021)

Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes
por: D'Onofrio, Luca, et al.
Publicado: (2021)

Up and down waves of glycemic control and lower-extremity amputation in diabetes
por: Caruso, Paola, et al.
Publicado: (2021)

Integrated insulin pump therapy with continuous glucose monitoring for improved adherence: technology update
por: Tumminia, Andrea, et al.
Publicado: (2015)

Diabetes and sexual dysfunction: current perspectives
por: Maiorino, Maria Ida, et al.
Publicado: (2014)

Lifestyle modifications and erectile dysfunction: what can be expected?
por: Maiorino, Maria Ida, et al.
Publicado: (2015)

Comment on Mäkimattila et al. Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study. Diabetes Care 2020;43:1041–1047
por: Bellastella, Giuseppe, et al.
Publicado: (2020)

Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus
por: Di Mario, Carlo, et al.
Publicado: (2022)

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
por: Esposito, Katherine, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses
por: Esposito, Katherine, et al.
Publicado: (2015)

Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
por: Longo, Miriam, et al.
Publicado: (2020)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring
por: Longo, M., et al.
Publicado: (2021)

European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events
por: di Mauro, Gabriella, et al.
Publicado: (2022)

Clinical Practice Recommendations on the Routine Use of Eversense, the First Long-Term Implantable Continuous Glucose Monitoring System
por: Deiss, Dorothee, et al.
Publicado: (2019)

The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
por: Kalra, Sanjay, et al.
Publicado: (2016)

Anti-Pituitary Antibodies and Hypogonadotropic Hypogonadism in Type 2 Diabetes: In Search of a Role
por: Bellastella, Giuseppe, et al.
Publicado: (2013)

Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy
por: Longo, Miriam, et al.
Publicado: (2019)

Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits
por: Pauley, Meghan E., et al.
Publicado: (2022)

The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism
por: Mahrooz, Abdolkarim, et al.
Publicado: (2021)

Devices for continuous monitoring of glucose: update in technology
por: Gómez, Ana María, et al.
Publicado: (2017)

Comment on: Wing et al. Effect of Intensive Lifestyle Intervention on Sexual Dysfunction in Women With Type 2 Diabetes: Results From an Ancillary Look AHEAD Study. Diabetes Care 2013;36:2937–2944
por: Maiorino, Maria Ida, et al.
Publicado: (2013)

Type 1 diabetes triggered by covid-19 pandemic: A potential outbreak?
por: Caruso, Paola, et al.
Publicado: (2020)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Cross-Talk between PPARγ and Insulin Signaling and Modulation of Insulin Sensitivity
por: Leonardini, Anna, et al.
Publicado: (2009)

Insulin and Insulin Receptors in Adipose Tissue Development
por: Cignarelli, Angelo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mihv4oh480ko9906n5edfq7oje